816 related articles for article (PubMed ID: 18617467)
1. [The pulmonological manifestations of rheumatoid arthritis].
Bernscherer G; Karabélyos C; Tarján Z
Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
3. Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate.
Sweet DD; Isac G; Morrison B; Fenwick J; Dhingra V
CJEM; 2007 Jan; 9(1):40-2. PubMed ID: 17391602
[TBL] [Abstract][Full Text] [Related]
4. [Case of rheumatoid arthritis presenting with pulmonary tuberculosis].
Katoh K; Taniguchi H; Okouchi A; Kudo M; Kawai T
Nihon Kokyuki Gakkai Zasshi; 2004 Aug; 42(8):782-6. PubMed ID: 15455955
[TBL] [Abstract][Full Text] [Related]
5. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
6. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
Wolfe F; Caplan L; Michaud K
Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
[TBL] [Abstract][Full Text] [Related]
7. [Non tuberculous anti-TNF associated opportunistic infections].
Marie I; Guglielmino E
Rev Med Interne; 2010 May; 31(5):353-60. PubMed ID: 20381217
[TBL] [Abstract][Full Text] [Related]
8. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
9. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
Curtis JR; Patkar N; Xie A; Martin C; Allison JJ; Saag M; Shatin D; Saag KG
Arthritis Rheum; 2007 Apr; 56(4):1125-33. PubMed ID: 17393394
[TBL] [Abstract][Full Text] [Related]
10. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
Asahina A; Ishii N; Tohma S
J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
[No Abstract] [Full Text] [Related]
11. Safety of biologic therapies--an update.
Keystone EC
J Rheumatol Suppl; 2005 Mar; 74():8-12. PubMed ID: 15742458
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
[TBL] [Abstract][Full Text] [Related]
13. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.
Sokolove J; Strand V; Greenberg JD; Curtis JR; Kavanaugh A; Kremer JM; Anofrei A; Reed G; Calabrese L; Hooper M; Baumgartner S; Furst DE;
Ann Rheum Dis; 2010 Sep; 69(9):1612-7. PubMed ID: 20448284
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
Strangfeld A; Hierse F; Kekow J; von Hinueber U; Tony HP; Dockhorn R; Listing J; Zink A
Ann Rheum Dis; 2009 Dec; 68(12):1856-62. PubMed ID: 19126559
[TBL] [Abstract][Full Text] [Related]
15. Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNFα therapy.
Schoffelen T; Kampschreur LM; van Roeden SE; Wever PC; den Broeder AA; Nabuurs-Franssen MH; Sprong T; Joosten LA; van Riel PL; Oosterheert JJ; van Deuren M; Creemers MC
Ann Rheum Dis; 2014 Jul; 73(7):1436-8. PubMed ID: 24794150
[No Abstract] [Full Text] [Related]
16. Therapies for active rheumatoid arthritis after methotrexate failure.
O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
[TBL] [Abstract][Full Text] [Related]
17. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
Ehlers S
J Rheumatol Suppl; 2005 Mar; 74():35-9. PubMed ID: 15742463
[TBL] [Abstract][Full Text] [Related]
18. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G;
J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
[TBL] [Abstract][Full Text] [Related]
19. [Pulmonary tuberculosis associated to adalimumab: a study of 3 cases].
Blanco Pérez JJ; Aranda Torres A; Pego Reigosa JM; Núñez Delgado M; Temes Montes E; Guerra Vales JL
Arch Bronconeumol; 2010 Apr; 46(4):203-5. PubMed ID: 19896259
[TBL] [Abstract][Full Text] [Related]
20. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
Koike R; Takeuchi T; Eguchi K; Miyasaka N;
Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
